Hernández-Blanco Clara, Al-Akioui-Sanz Karima, Herrera Lara, Aguirre-Portolés Cristina, Lozano-Ojalvo Daniel, Pérez-Rodriguez Leticia, Cano-Ochando Jordi, Guerra-García Pilar, Martín-Quirós Alejandro, Vicario José Luis, Santos Silvia, Pérez-Vaquero Miguel Ángel, Vesga Miguel Ángel, Borobia Alberto M, Carcas Antonio J, Balas Antonio, Moreno Miguel Ángel, Pérez de Diego Rebeca, Gasior Mercedes, Soria Bernat, Eguizabal Cristina, Pérez-Martínez Antonio
Internal Medicine Department, University Hospital La Paz, Madrid, Spain.
Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
iScience. 2024 Dec 27;28(2):111698. doi: 10.1016/j.isci.2024.111698. eCollection 2025 Feb 21.
The severity of COVID 19 symptoms has a direct correlation with lymphopenia, affecting natural killer (NK) cells. SARS-CoV-2 specific "memory" NK cells obtained from convalescent donors can be used as cell immunotherapy. In 2022 a phase I, dose-escalation, single center clinical trial was conducted to evaluate the safety and feasibility of the infusion of CD3/CD56 NK cells against moderate/severe cases of COVID-19 (NCT04578210). Six participants with pneumonia and/or lymphopenia were infused. Four patients received a single-dose infusion of NK cells of 1×10/kg, and the following two patients a dose of 2×10/kg of NK cells. All participants' clinical status and inflammation markers were monitored. No serious adverse events were reported after infusion. Exploratory outcomes included the donor chimerism, NK-cell immunophenotype evolution, and immune lymphocyte reconstitution. This study provides preliminary evidence supporting the idea that treatment of COVID-19 patients with moderate/severe symptoms using NK from COVID-19 convalescent donors is feasible and safe.
新冠病毒 19 症状的严重程度与淋巴细胞减少直接相关，影响自然杀伤（NK）细胞。从康复供体获得的新冠病毒 2 特异性“记忆”NK 细胞可用于细胞免疫治疗。2022 年进行了一项 I 期、剂量递增、单中心临床试验，以评估输注 CD3/CD56 NK 细胞治疗中度/重度新冠病毒 19 病例（NCT04578210）的安全性和可行性。六名患有肺炎和/或淋巴细胞减少的参与者接受了输注。四名患者接受了 1×10/kg 的 NK 细胞单剂量输注，随后两名患者接受了 2×10/kg 的 NK 细胞剂量输注。监测了所有参与者的临床状况和炎症标志物。输注后未报告严重不良事件。探索性结果包括供体嵌合现象、NK 细胞免疫表型演变和免疫淋巴细胞重建。本研究提供了初步证据，支持使用来自新冠病毒 19 康复供体的 NK 细胞治疗中度/重度症状的新冠病毒 19 患者是可行且安全的这一观点。
